{"url":"https://lda.senate.gov/api/v1/filings/ae00cbcd-be21-4bf0-8258-b3ed1012f4b3/","filing_uuid":"ae00cbcd-be21-4bf0-8258-b3ed1012f4b3","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2022,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/ae00cbcd-be21-4bf0-8258-b3ed1012f4b3/print/","filing_document_content_type":"text/html","income":null,"expenses":"260000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon","dt_posted":"2022-10-19T21:14:39-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.senate.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.senate.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Drug pricing issues: H.R. 5376, Inflation Reduction Act of 2022; Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023; Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Drug Pricing Issues: H.R. 5376, Inflation Reduction Act of 2022; Nursing Home Quality: S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act; Six Protected Classes resolution: H. Res. 1390, Expressing support for the protection of Medicare part D's six protected classes","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Nursing Home Quality: S. 4659 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Rett Syndrome Research: H.R. 8236, Department of Defense Appropriations Act, 2023","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}